Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.54 |
| ▸ | USP2 | O75604 | 5/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | FLT3 | P36888 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3481934 | 0.92 | USP2 (0.44) | CYP1A2CYP3A4CYP2D6CLK4USP2 | |
| SCHEMBL2180622 | 0.90 | USP2 (0.42) | CYP1A2CYP3A4CYP2D6CLK4USP2 | |
| SCHEMBL5523470 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP3A4CYP2D6CLK4USP2 | |
| SCHEMBL2169294 | 0.77 | KCNA5 (0.59) | ALDH1A1KDM4EPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2169804 | 0.77 | KCNA5 (0.59) | ALDH1A1KDM4EPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2169298 | 0.77 | KCNA5 (0.59) | ALDH1A1KDM4EPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1085578 | 0.75 | CYP1A2 (0.79) | CYP1A2CYP3A4CYP2D6CLK4USP2 | |
| SCHEMBL2168279 | 0.74 | KDM4E (0.49) | CYP1A2CYP3A4CYP2D6HSD17B10CYP2C19 | |
| SCHEMBL2168526 | 0.73 | ADORA2A (0.48) | ALDH1A1KDM4ERAD52KMT2ASMN1; SMN2 | |
| SCHEMBL3482350 | 0.73 | KCNA5 (0.46) | CYP1A2CYP3A4CYP2D6USP2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4722851-B2 | — | — | 2011-07-13 | — | — | JP | claimed |
| US-7692017-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | claimed |
| EP-1667683-A4 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1667683-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005030129-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | claimed |
| US-7692017-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692017-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692017-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1667683-A4 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| EP-1667683-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030129-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | KCNH2, KCNJ2, KCNQ1 | CYP1A2 321/4885CYP3A4 348/4885CYP2D6 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.